e-ESO Podcasts: Recent Episodes
ESO - European School of Oncology
e-ESO is the online platform of the European School of Oncology providing sponsor-free, open access quality education wherever you are in the world. www.e-Eso.net
Expert: Joana Liz Pimenta, ICBAS- Abel Salazar Institute of Biomedical Sciences, Porto, Portugal
Expert: Radwa Hamed Sabra, Lecturer of Clinical Oncology, Armed Forces College of Medicine Egypt, Cairo, Egypt
Experts:
João Coelho, Centro Hospitalar Universitário de Santo António, Porto, PT
Paula Fidalgo, Centro Hospitalar Universitário de Santo António, Porto, PT
Expert: Franco Cavalli, Foundation for the Institute for Oncology Research (IOR), Bellinzona, Switzerland
Expert: Zaiana Sangadzhieva, Institute for Personalized Oncology of Sechenov University, Moscow, RU
Experts:
Sara Ramella, Campus Bio-Medico University, Rome, Italy
Pierfilippo Crucitti, Campus Bio-Medico University, Rome, Italy
Expert: Stefania Volpe, European Institute of Oncology Milan and University of Milan, Milan, Italy
Expert: Malgorzata Osmola, University Clinical Centre - Medical University of Warsaw, Warsaw, Poland
Fellow: Silvia Brotea-Mosoiu, Oncology Institute of Bucharest, Bucharest, Romania
Mentor: Salvatore Provenzano, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Expert: Ilaria Colombo, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
Expert: Patricia Fox, UCD School of Nursing, Midwifery and Health Systems, Dublin, Ireland
Expert:
Anna Mironova, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
Experts:
Giovanni Boniolo, University of Ferrara, Ferrara, IT
Fedro A. Peccatori, European Institute of Oncology, Milan, Italy
Experts:
Ramon Andrade Bezerra de Mello, Oxford Cancer Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
Anna Mironova, I.M. Sechenov First Moscow State Medical University, Moscow, RU
Experts:
Hatem A. Azim Jr., Monterrey Institute of Technology, Monterrey, Mexico
Matteo Lambertini, University of Genova - San Martino Hospital, Genoa, Italy
Experts:
Rasha Mohamed AbdelMotagalee Aboelhassan, Nasser Institute, Cairo, Egypt
Asmaa Mohamed Taha, Nasser Institute, Cairo, Egypt
Experts:
Mohamed Emam Salah Emam Sobeih, National Cancer Institute Cairo, Nasr City, Egypt
Hala Aziz, National Cancer Institute, Cairo, Egypt
Expert: Andrei Kachmazov, P. A. Hertsen Moscow Oncology Research Center, Moscow, Russian Federation
Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy
Experts:
Mohamed Emam Salah, National Cancer Institute Cairo, Nasr City, Egypt
Rasha Mohamed AbdelMotagalee Aboelhassan, Nasser Institute Hospital, Cairo, Egypt
Expert: Giuseppe Luigi Banna, Portsmouth Hospitals University NHS Trust, Portsmouth, UK
Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy
Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy
Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy
Expert: Ornella Garrone, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Experts:
Ramon Andrade Bezerra de Mello, Nine of July University (UNINOVE), Sao Paulo, Brazil
Thais Vazquez, University of São Paulo and Cancer Institute of State the São Paulo, Sao Paulo, Brazil
Experts:
Ursula Vogl, Cantonal Hospital of Southern Switzerland, Bellinzona, Switzerland
Niklaus Schaefer, University Hospital of Canton Vaud, Lausanne, Switzerland
Experts:
Raffaele Giusti, Sant’Andrea Hospital, Rome, Italy
Giampiero Porzio, Associazione Tumori Toscana, Florence, Italy
Expert: Dr Bertha Alejandra Martinez-Cannon, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Experts:
Yusuf Ziya Sener, Hacettepe University Faculty of Medicine, Ankara, Turkey
Evandro de Azambuja, Br.E.A.S.T. Data Centre, Jules Bordet Institute, Brussels, Belgium
Expert: Michele Ghidini, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
Expert: Mónica Isabel Meneses Medina, National Institute of Health Sciences and Nutrition “Salvador Zubirán”, Mexico City, Mexico
Expert: Malgorzata Osmola, University Clinical Centre Medical University of Warsaw, Warsaw, Poland
Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy
Experts:
Berardino De Bari, Radiation Oncologist, Réseau Hospitalier Neuchâtelois, La Chaux-de-Fonds, Switzerland
Ilaria Colombo, Medical oncologist, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
Expert: Diana Artene, Sc Medikin SRL, Bucharest, Romania
Questions:
- What is obesity impact on breast cancer treatment efficacy and side effects
- What is a ketogenic diet?
- Do we have safety and efficacy data for recommending ketogenic diets to breast cancer patients?
- Are there metabolic differences between different immunohistochemical breast cancer subtypes?
- What is the take home message for our breast cancer patients?
Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy
Experts:
Joana Ribeiro, Gustave Roussy Institute, Villejuif, France
Ana Tecic Vuger, University Hospital for Tumors, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia
Expert: Alessandra Curioni-Fontecedro, University Hospital Zurich, Zurich, Switzerland
Questions:
1.What's the accurate definition of immunotherapy rechallenge?
2.When we could rechallenge with immunotherapy after failure of previous I.O based therapy ?
3.There is any biomarkers to guide us in I.O rechallenge?
4.Which type of I..O could be used after failure of previous I.O?
5.what is the current trials that investigate this type of therapy?
Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy
Expert: Nicola Fusco, University of Milan and IRCCS European Institute of Oncology, Milan, IT
Expert: Maggie Banys Paluchowski, University Hospital Schleswig-Holstein (UKSH), Lübeck, DE
Questions:
1-Why do we need localization techniques?
2-How to perform intraoperative ultrasound?
3-Can you comment on the available evidence on intraoperative ultrasound?
4-What can be potential problems of intraoperative ultrasound?
5-What about intraoperative ultrasound in palpable lesions?
Expert: Luca Bertolaccini, Thoracic Surgeon, European Institute of Oncology, Milan, Italy
Expert
Ramon Andrade Bezerra de Mello, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil
Questions:
1-How to clinically approach metastatic gastric cancer in terms of molecular biomarkers?
2-What is the best sequence treatment for advanced gastric cancer?
3-How to approach the second line and beyond in advanced gastric cancer?
4-Perspectives of the ICI combinations for advanced gastric cancer?
Expert: Ilaria Colombo, Oncology Institute of Southern Switzerland, Bellinzona, CH
Questions:
1-Which is the mechanism of action of PARP inhibitors and why this is relevant in ovarian cancer?
2-How can we measure the homologous recombination deficiency?
3-Which is the current evidence for the use of maintenance PARP inhibitors in recurrent epithelial ovarian cancer?
4-Can you tell us which are the results of phase 3 trials that have investigated PARP inhibitors in front line treatment of epithelial ovarian cancer?
5-Which are the main toxicities of PARP inhibitors?
Expert: Christos Sotiriou, Institute Jules Bordet, Bruxelles, BE
Questions:
1-How do you define clinician-scientists?
2-In 2014 Baumal et al reported that the number of clinician-scientists has decreased ,do you think this is the case in 2021 too?
-if yes could you elaborate on reasons behind graduates opting out of this option
3-Are mentors determining the path fellows are taking in regard to clinician-scientists?
4-Is it more beneficial to do science and clinics separately?
5-What is the benefit to society of clinicians conducting scientific research?
Expert: Anastasios Stathis, Oncology Institute of Southern Switzerland, Bellinzona, CH
Questions:
1-How drug-drug interactions can be defined?
2-How frequent they are?
3-Can you make some examples with new drugs approved for lymphoid malignancies?
4-Do all new drugs have the same risk of interactions?
5-What is the best management?
Expert: Ramon Andrade Bezerra de Mello, Sao Paulo, Brazil
Questions:
1-Stage 3 colon cancer did operation and competed adj chemo (capeox) . after 1 year developed single lung lesion, resection done but the margin was positive!, radiotherapy could not be given due to unmarking of resection site, we gave her same adj chemo, after 4 month from completion if chemo developed wide spread dz in lung an live!
2-Stage 3 colon cancer, emergency operating done due to obstruction , resection margin positive! re operation could not be done because she developed lots of post op complications ( leak), we gave her adj chemo!
3-In positive resection margins, should we manage as stage 4?
4-Stage 3 gastric cancer, received 4 cycle per op FLOT, during operation small single live lesion was detected, which was resected too, negative margin, and pathologically proved to be met, shall we manage as stage 4 or complete the 4 FLOT?
Expert: Elisa Gobbini, Gustave Roussy Institute, Villejuif, FR
Questions:
1-What is the role of immunotherapy in PD-L1 negative mNSCLC?
2-Could you describe the rational for cases with negative PDL1 responding to immunotherapy?
3-What about liquid PDL-1 assay and how to be implemented in clinical practice?
4-How long the duration required for re-exposition to previously received immunotherapy?
5-Patients with history of auto-immune diseases, there are any criteria to select the patient who will be candidate to receive immunotherapy or not?
Expert: Giancarlo Pruneri, National Cancer Institute - IRCCS Foundation, Milan, Italy
Questions:
1-Can You explain what is meant by the title „low positive“ luminal breast cancer?
2-Is that treshold (<10%) uniform everywhere, in the entire oncology /pathology/ community?
3-What are the guidelines to follow on this question?
4-Can You comment on the two tresholds for defining positive HR status (≥1% vs ≥10%)?
5-Is there an implication on therapeutic approach (i.e. how should we be treating these cases, should they receive ET)? Please explain.
Expert: Ines Vaz-Luis, Gustave Roussy Institute, Villejuif, France
Questions:
1-Alleviating hot flashes on hormonal therapy (including complimentary medicine).
2-Bone targeting agents in patients on adjuvant hormonal therapy (calcium and vitamin D, bisphosphonates, denosumab).
3-Treatment of neuropathy (after taxanes or platinum agents).
4-Alleviating neurocognitial disorders.
Expert: Richard Anderson, University of Edinburgh, Edinburgh, UK
Questions:
1- Frequency of fertility loss (in men and women) after most often chemotherapy regimens used in young patients with cancer (ABVD, BEACOPPesc, others, targeted therapies).
2- Effectiveness of ovarian function suppression by GnRH analogues in women as a means of fertility preservation.
3- Effectiveness of various fertility preservation techniques (sperm preservation, oocyte cryopreservation and others) in conjunction with cancer treatment.
4- Timing and peculiarities of pregnancy after cancer treatment (mostly Hodgkin and non-Hodgkin lymphoma, breast cancer).
5- Peculiarities of ovulation stimulation in breast cancer patients (HR+ and HR-).
Expert: Nadia Harneck, Breast Center, LMU University Hospital, Munich, Germany
Questions:
1.The best hormonal partner: evidence on fulvestrant, letrozole or anastrozole.
2.Possibility to use CDK4/6i+AI in mBC in patients progressing during or after completion of adjuvant AI treatment.
3.Ways of overcoming haematologic toxicities (neutropenia, leucopenia).
4.Any evidence on choosing between three drugs of this class currently available (palbociclib, ribociclib, abemaciclib).
5.Possible biomarkers of response and effectiveness.
Expert: Giulia Baciarello, National Cancer Institute - IRCCS Foundation, Milan, Italy
Questions:
1-Is there a specific patient group in which you prefer using chemotherapy instead of androgen receptor pathway inhibitors?
2-Are there any clinical factors aiding the selection between abiraterone and enzalutamide?
3-Should we refrain from abiraterone treatment in patients with diabetes?
4-What should be the optimal treatment line for Lu-177 PSMA treatment in castration-resistant prostate cancer?
5-Is there a role of immunotherapy in castration-resistant prostate cancer in current clinical practice?
Expert: Paolo Bossi, University of Brescia, ASST Spedali Civili, Brescia, Italy
Questions:
1-Is there a role for induction chemotherapy for head and neck squamous cell carcinoma other than laryngeal preservation?
2-Could we use weekly cisplatin instead of high-dose three-weekly cisplatin concomitantly with radiotherapy?
3-Do you prefer cetuximab or carboplatin for chemoradiotherapy in patients ineligible for cisplatin?
4-What is the current role of positron emission tomography (PET) in patients with localized head and neck squamous cell carcinoma?
5-What’s the best option for induction chemotherapy in nasopharyngeal cancer (docetaxel-cisplatin-5FU or gemcitabine-cisplatin)?
Expert: Wendy McInally, Open University Edinburgh, United Kingdom
1-Is Melanoma (skin cancer) common in young people across the globe?
2-What are the main signs and symptoms for young people and/or the family to look out for?
3-How is melanoma in young people diagnosed?
4-What is the treatment for melanoma in young people?
5-Where are young people ‘normally’ treated and cared for?
Expert: Tanja Cufer, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia
Questions:
1-What are the first baby steps recent oncology graduates can take to advance their international career?
2-If ones country doesn’t provide proper training in conducting research what do you suggest for substitution?
3-Is it advisable(plausable) to take a break from clinics to do research abroad?
4-Can one person from another country join a coalition of centers to conduct joint study?
5-Do you believe networking is a key to globalization of science?
Expert: Michael Gnant, Comprehensive Cancer Center Vienna, Vienna, Austria
Questions:
1.What is the recommendation for use of bisphosphonates in eBC? Which agents? How long? To which patients?
2.What is the benefit of adjuvant bisphosphonates in eBC (breast cancer - related outcomes and other benefit)?
3.What is the recommendation for use of denosumab in eBC?
4.What are the data to support these recommendations for practice?
Expert: Rosa Di Micco, San Raffaele University and Research Hospital, Milan, Italy
Questions:
1-Is pathological sampling mandatory?
2-If positive, it imply in axillary dissection?
3-If clinically LN+ is possible to perform only asentinel lymph node biopsy at surgery?
Expert: Nicholas Pavlidis, University of Ioannina, Ioannina, Greece
Questions:
1-What do we know about CUP?
2-What do we know about the impact of genomic analysis in CUP diagnosis and treatment?
3-What standard diagnostic work-up is recommended to have completed, before a case can be called a CUP case?
4-Does speeding up the diagnostic process help patients’ outcome?
5-How doctors transfer the bad news about CUP diagnosis and outcome to the patients? Does support with palliative care helps CUP patients?
Expert: Stein Kaasa, Oslo University Hospital, Oslo, NO
Questions:
1-Who should be a part of the palliative care team?
2-When to switch palliative care to cancer patients' care?
3-The impact of COVID-19 pandemic on palliative care?
4-How to improve palliative care quality in developing countries?
5-New methods of pain control.
Experts:
Alessandra Curioni-Fontecedro, University Hospital Zurich, Zurich, CH
Giuseppe Banna, Portsmouth Hospitals University NHS Trust, Portsmouth, UK
Questions:
1.In patients who have received chemo immunotherapy ad first line treatment for advanced NSCLC, would you consider a re-challenge with two immunotherapies as an option? (patients who did not experience any irAE)
2.In case of First line Immunotherapy alone, would you consider chemo immunotherapy in second line or chemotherapy alone? (patients who did not experience any irAE)
3.In case of progression after first line, do you recommend a re-biopsy?
4.What is you preferred second line treatment of choice after chemo-immunotherapy?
5.In case a patient experienced response to chemotherapy +immunotherapy in first line and progresses on immunotherapy maintenance, would you re-challenge the patient with the same chemotherapy given in first line?
Expert: Nikolaos Tsoukalas, 401 General Military Hospital, Athens, Greece
1-What is the association between cancer and thrombosis? Why should we care?
2-What are the principles of thromboprophylaxis in oncology patients? (Guidelines and recommendations)
3-What are the main clinical features of coagulopathy in COVID-19 disease?
4-Is the cumulative thrombotic risk like a “perfect thrombotic storm” in oncology patients during COVID-19 pandemic?
5-Making clinical decisions regarding CAT management taking into consideration the potential cumulative thrombotic risk in COVID-19 era. Should oncologists modify their clinical practice?
Expert: Joana Ribeiro, Champalimaud Clinical Center, Lisbon, Portugal
1-Define breast cancer with NE differentiation and distinguish it from NEC
2-Discuss neuroendocrine differentiation as an independent adverse prognostic factor for shorter OS / DFS
3-Discuss Ki 67and differentiation between NET / NEC and OS / DFS
4-Discuss adjuvant treatment- according to the same recommendations given for the other types of invasive breast cancer?
5-In the metastatic setting: types of chemotherapy in NEC and multimodality approach including specific therapies such as peptide receptor radionuclide therapy
Expert: Luca Bertolaccini, European Institute of Oncology, Milan, Italy
1-What is a systematic review_meta analysis
2-What is the clinical question that needs to be answered
3-How to perform a correct search strategy
4-How to perform the study selection
5-How to perform the statistical analysis
Expert: Olivia Pagani, Riviera-Chablais Hospital, Rennaz, Switzerland
Questions:
1-Which is the definition of young women and why do we need a definition?
2-Which are the challenges in treating breast cancer in young women?
3-Why do we need guidelines?
4-Which are the key differences and specifities in their treatment?
5-Beyond the therapeutic strategies, what should we address when taking care of young breast cancer patients?
Expert: Astrid Pavlovsky, Clinical Research Center - FUNDALEU, Buenos Aires, Argentina
1 - Why do chemorefractory patients respond to checkpoint inhibitors?
2 - Can you comment on the design and results of the KEYNOTE 204 for patients with RR HL?
3 - What do you think are the future challenges and therapeutic options in this group of patients?
Expert: Maria Alice Franzoi, Jules Bordet Institute, Brussels, Belgium
Questions:
1 - Can you describe a visceral crisis to us?
2 - What about a work up and evaluation of liver disfunction in breast cancer?
3 - Can you explain how to manage liver disfunction with supportive care?
4 - Which agents should we use and with what dosage in the role of systemic treatment in liver disfunction?
Experts:
Giancarlo Pruneri, National Cancer Institute, Milan, Italy
Catarina Eloy, Ipatimup Institute, Porto, Portugal
Expert: Stephan Rauh, Hospital Center Emile Mayrisch, Esch-sur-Alzette, Luxembourg
Questions:
1- What would be your approach to patients for whom anticoagulation is of uncertain benefit, for example with active malignant disease in pelvis creating continuous venous compression and conditions for recurrent or progressive thrombosis?
2- In a cancer patient with creatinine clearance bellow 30 mcmol/ l what would be your anticoagulant of choice for the treatment of a tromboembolic event (DVT/PE)?
3- In a patient with a chemotherapy- induced trombocytopenia bellow 50 x 10^9/l and active PE what would be your choice of LMWH?
4- Due to Covid pandemic there is a shortage of LMWHs in our country. If LMWHs were unavailable, what would be your first choice of alternative anticoagulant for the prophylaxis or treatment of thromboembolic events in cancer patients?
5- In a premenopausal women diagnosed with estrogen receptor positive high risk early breast cancer (node positive with more than 4 involved lymph nodes) with a high risk for thromboembolic events (history of thrombophilia) who opt for a pregnancy and do not tolerate LHRH analogs in combination with aromatase inhibitors? Would tamoxifen be an option with or w/o anticoagulant prophylaxis?
Expert: Pierfrancesco Franco, University of Eastern Piedmont, Novara, Italy
Questions:
1- Why job is so important for people’ s life?
2- What is burn-out and what are its main characteristics?
3- What are the causes of burnout and decreased professional well-being?
4- Why burn-out is a crucial issue for healthcare providers, particularly in the field of oncology, and what are its consequences?
5- What are the potential interventions able to prevent burnout in the working environment?
Expert: Fatima Cardoso, Champalimaud Clinical Center, Lisbon, Portugal
Questions:
1- Why did you chose this topic for the Umberto Veronesi memorial award lecture?
2- Can you please give examples of deascalation or optimization for early breast cancer?
3- Can you now give examples of deascalation or optimization for advanced breast cancer?
4- And examples for drug development?
5- Would you like to add any final comments?
Expert: Andrés Cervantes Ruiperez, Hospital Clinico Universitario, Valencia, Spain
Questions:
1- When to give adjuvant chemotherapy for rectal cancer after chemo-radiation?
2- When do you recommend a total neoadjuvant treatment (TNT) and which is your preferred protocol?
3- In your clinical practice, would you consider a wait and see strategy, for those patients achieving a complete remission after TNT?
4- How to prioritize treatment of metastatic rectal cancer: when to give systemic therapy first and when to go for surgery and radiation?
Expert: Agata Rembielak, The Christie NHS Foundation Trust, Manchester, United Kingdom
Questions:
1- Should we all worry about skin cancer and how common is it?
2- What are the recent developments in skin radiotherapy?
3- How successful is skin radiotherapy and which patients should consider this option?
4- Is there a role of systemic treatments in keratinocyte tumours?
5- What about the psychosocial aspect in skin cancer?
Expert: Berardino De Bari, Réseau Hospitalier Neuchâtelois, La Chaux-de-Fonds, Switzerland
Questions:
1- Moderate hypofractionation is considered a standard of care in prostate radiotherapy. What is the state of the art in 2021 for extreme hypofractionation in prostate cancer?
2- What’s your point of view about the multidisciplinary approach to locally advanced prostate cancer?
3- Some very recent studies seems to close the neverending debate on adjuvant vs salvage radiotherapy. Could you summarize these findings?
4- Is there a role for local treatments in metastatic prostate cancer?
5- PSMA PET/CT is clearing changing the approach to prostate cancer. Could you summarize us how it can impact the therapeutic strategy for prostate cancer patients?
Expert: Oriana Ciani, Associate Professor of practice SDA Bocconi School of Management, Milan, Italy
Questions:
1- What is a surrogate endpoint?
2- What are the advantages of using surrogate endpoints?
3- What are the pitfalls, instead?
4- How do we appropriately validate and apply surrogate-based evidence?
5- How do present surrogate measures in oncology measure up?
Expert: Nicola Rocco, University of Naples Federico II, Naples, Italy
Questions:
1- What is Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)?
2- What is the clinical presentation of BIA-ALCL?
3- How can I diagnose BIA-ALCL?
4- How can I stage BIA-ALCL?
5- What is the treatment for BIA-ALCL?